Maybio raises $4.5M Series B for human-derived ECM materials
What's the deal? MaybioDealroom has a profile for this one. Try Dealroom →, a developer of human-derived extracellular matrix (ECM) regenerative materials, has raised US$4.13M (roughly $4.5 million) in a Series B round. The round was backed by an industrial fund under grand industrial financial fund (远大产融).
What's the endgame? The company is building a full-chain platform for regenerative materials, covering research, production, and sales. Its business spans medical aesthetics and functional skincare products, maxillofacial repair scaffolds, stem cell-derived raw materials, and contract research and manufacturing services.
Why it matters: Maybio says it was the first to achieve mass production of human-derived ECM. It claims to run the world's largest research and production base for the material, with vaccine-grade manufacturing processes and biopharmaceutical quality-control standards.
Kaicheng CapitalDealroom has a profile for this one. Try Dealroom → served as the exclusive financial adviser on the deal, which was announced in September 2026.
The signal: Investor interest in regenerative biomaterials is feeding a growing overlap between medical aesthetics and biopharma-grade manufacturing. Maybio's raise underscores demand for scalable, high-standard production of next-generation materials serving both skincare and clinical repair markets.
Image credit: Generated with Gemini
